GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Acelyrin Inc.
Acelyrin, a biotech company, shares reflect the potential of its lead drug for treating inflammatory diseases. The trajectory of its price after a successful IPO will depend on the results of late-stage clinical trials and competition.
Share prices of companies in the market segment - Pharma other
Acelyrin is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of immunological diseases. We classify it as "Other Pharma." The chart below shows how investors value companies operating in this broad and competitive field of medicine.
Broad Market Index - GURU.Markets
Acelyrin is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of immunological diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Acelyrin shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SLRN - Daily change in the company's share price Acelyrin Inc.
Acelyrin, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its immune-diseases drugs.
Daily change in the price of a set of shares in a market segment - Pharma other
Acelyrin is a biopharmaceutical company specializing in the development of drugs to treat immunological diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this sector, allowing you to assess the performance of SLRN stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Acelyrin is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Acelyrin Inc.
Acelyrin, Inc.'s year-over-year performance is a story about the development of its immune disease treatment. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead candidate, which could offer greater efficacy than existing blockbusters, would be a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Pharma other
Acelyrin, a late-stage biotech company, develops drugs to treat immunological diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Acelyrin is a biotech company whose value is locked into its pipeline of drugs. Its shares move with news about clinical trials, not economic cycles. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Acelyrin Inc.
Acelyrin is a biopharmaceutical company. Its monthly performance is typical for the sector: it depends on progress in its scientific developments and clinical programs. News of trial results for its immune disease drugs are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma other
Acelyrin is a late-stage biopharmaceutical company focused on developing drugs for the treatment of immunological diseases. Its strategy is to acquire and develop promising assets. The chart below shows the overall dynamics of the biotech sector, where successful clinical trials are the main value driver.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Acelyrin is a biotech company developing drugs to treat immunological diseases. Its shares are buoyed by anticipation of clinical trial results. Positive data can trigger explosive growth, while failures can lead to a collapse, and these events are in no way related to the overall state of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Acelyrin Inc.
The weekly performance of biotech company Acelyrin reflects the high stakes in immunology. Shares are reacting sharply to clinical trial data for their key drug, which could become a new blockbuster for the treatment of inflammatory diseases.
Weekly dynamics of market capitalization of the market segment - Pharma other
Acelyrin is a biotech company developing drugs to treat immunological diseases. The chart will help separate its own news-driven dynamics from the overall fluctuations in the pharmaceutical sector, showing how the market views its pipeline and its chances of success.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Acelyrin is a biopharmaceutical company. Its success depends on the results of clinical trials. This chart will help us understand: does Acelyrin live in its own world of scientific news, or are the overall market conditions and risk appetite in the biotech sector actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
SLRN - Market capitalization of the company Acelyrin Inc.
Acelyrin's market capitalization tells the story of a biotech company that raised record amounts of money in its IPO. Its subsequent decline is a dramatic account of the failure of its lead drug in key clinical trials. The dynamics are a striking example of how quickly the greatest hopes in biotech can crumble.
SLRN - Share of the company's market capitalization Acelyrin Inc. within the market segment - Pharma other
Acelyrin is a biotech company focused on immunology. Its share of its segment's market capitalization reflects the high expectations surrounding its lead drug candidate. The chart shows how its share changes based on the results of key clinical trials.
Market capitalization of the market segment - Pharma other
Acelyrin is a biotech company focused on immunology. The chart below shows the overall market capitalization of this knowledge-intensive sector. Its volatile dynamics reflect the hopes and disappointments that accompany the long journey to developing new drugs to treat complex diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Acelyrin is a biotech company. The market capitalization of clinical-stage companies reflects investors' faith in the scientific hypothesis and the team. Their volatility on the overall chart reflects the long and risky journey from an idea to a potential life-changing drug.
Book value capitalization of the company, segment and market as a whole
SLRN - Book value capitalization of the company Acelyrin Inc.
Acelyrin's book value reflects its massive capital raised for the late-stage development and commercialization of drugs for the treatment of immunological diseases. This provides the tangible, financial, and scientific foundation for bringing potential blockbusters to market. How has this "rich" biotech asset changed? The chart below shows its dynamics.
SLRN - Share of the company's book capitalization Acelyrin Inc. within the market segment - Pharma other
Acelyrin is a biopharmaceutical company developing drugs to treat immunological diseases. The chart shows the share of its R&D assets, reflecting the physical foundation on which the company conducts its clinical trials.
Market segment balance sheet capitalization - Pharma other
Acelyrin, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Acelyrin's balance sheet isn't its factories, but its intellectual property for the drug isebvalimab, which is potentially best-in-class for the treatment of a number of immune diseases. The company's assets are capitalized science. The chart below shows how this promising biotech stacks up in terms of assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Acelyrin Inc.
Acelyrin, Inc. is a biotech company focused on immunology. Its balance sheet reflects the acquisition and development costs of promising drugs. Its market capitalization reflects investors' high valuation of its key drug's potential to become a blockbuster. The chart reflects high expectations for its flagship product.
Market to book capitalization ratio in a market segment - Pharma other
Acelyrin is a biotech company developing drugs for the treatment of immunological diseases. Its market valuation on the chart reflects the high potential of its lead drug candidate, which has the potential to become best-in-class, attracting significant investor interest.
Market to book capitalization ratio for the market as a whole
Acelyrin, Inc. is a clinical-stage biopharmaceutical company. Its value is almost entirely determined by investor expectations regarding the success of its developments. This chart clearly demonstrates how high the premium for a potential medical breakthrough can be compared to the average market valuation.
Debts of the company, segment and market as a whole
SLRN - Company debts Acelyrin Inc.
Acelyrin, Inc., a late-stage biotech, uses capital to fund large-scale clinical trials of its immunology drugs. This chart shows how the company raises massive amounts of capital to bring potential blockbusters to market, requiring a willingness to make significant and risky investments.
Market segment debts - Pharma other
Acelyrin is a late-stage biotech company developing drugs to treat immunological diseases. Funding large, final-stage clinical trials requires significant resources. This chart shows how the company raises capital, primarily equity, to bring its promising assets to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Acelyrin Inc.
Acelyrin is a biotech company focused on drugs for the treatment of immunological diseases. Its operations require significant investment in clinical research. This chart shows the extent to which the company relies on debt to finance its development, which is a measure of its financial risk on the path to commercialization.
Market segment debt to market segment book capitalization - Pharma other
Acelyrin is a biotech company that acquires and develops promising drugs for the treatment of immunological diseases. The chart illustrates how aggressively the biotech sector uses debt to finance expensive clinical trials, providing context for assessing Acelyrin's financial strategy and risks.
Debt to book value of all companies in the market
Acelyrin, Inc., a biopharmaceutical company focused on immunology, requires significant investment to conduct large-scale clinical trials. This chart, showing the overall market debt load, provides context. It helps assess how the company's capital raising strategy aligns with its ambitions to bring new drugs to market.
P/E of the company, segment and market as a whole
P/E - Acelyrin Inc.
Acelyrin is a clinical-stage biopharmaceutical company focused on developing drugs to treat immunological diseases. This chart shows how investors value its leading asset. The company's valuation is heavily dependent on clinical trial results and its potential in a competitive market.
P/E of the market segment - Pharma other
Immunology, where Acelyrin develops new drugs, is a promising field. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Acelyrin is valued as a research project, and its value depends on the success of clinical trials of its drugs for the treatment of autoimmune and inflammatory diseases.
P/E of the market as a whole
Acelyrin is a biopharmaceutical company specializing in the development of drugs for the treatment of immunological diseases. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. The overall market sentiment reflected in this chart is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Acelyrin Inc.
This chart for Acelyrin, Inc., a late-stage biopharmaceutical company, shows market expectations for its lead drug candidate. It reflects investor confidence that its immunology drug will be a blockbuster once approved.
%20P%2FE%20Acelyrin%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Acelyrin-Inc.&v=1772608041740 "Chart of the company's future (projected) P/E Acelyrin Inc.")
Future (projected) P/E of the market segment - Pharma other
Acelyrin is a late-stage biopharmaceutical company specializing in immunological diseases. Its lead candidate is designed to treat psoriatic arthritis and other conditions. The chart shows industry forecasts, helping to assess the market's perception of Acelyrin's potential to become a blockbuster.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772608041835 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Acelyrin, Inc. is a biopharmaceutical company specializing in immunology. The company's valuation depends on the success of its clinical developments. This graph of overall risk appetite shows how willing investors are to invest in long-term, risky biotech projects targeting large markets.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772608041915 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Acelyrin Inc.
Acelyrin, Inc. is a biopharmaceutical company focused on the development and commercialization of immunology drugs. Being in late-stage clinical trials, it is incurring significant losses. This chart illustrates the enormous costs required to bring a potential blockbuster to market in a competitive field.
Profit of companies in the market segment - Pharma other
Acelyrin is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of immunological diseases. This chart, which shows profitability in the pharmaceutical sector, demonstrates the size of the market for these diseases. Their lead drug targets conditions such as psoriatic arthritis, and its success depends on the results of clinical trials.
Overall market profit
Acelyrin, Inc. is a late-stage biopharmaceutical company focused on immunology. Its lead candidate is designed to treat various inflammatory diseases. Success depends on clinical trial results and regulatory approval. This gross profitability chart reflects the investment climate, which is important for funding such large R&D projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Acelyrin Inc.
Acelyrin is a biopharmaceutical company developing drugs to treat immunological diseases. Its lead candidate targets a broad range of inflammatory conditions. This chart summarizes analyst opinions on the clinical prospects and commercial potential of their flagship drug in the vast immunology market.
%20profit%20of%20the%20company%20Acelyrin%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Acelyrin-Inc.&v=1772608042128 "Graph of future (projected) profit of the company Acelyrin Inc.")
Future (predicted) profit of companies in the market segment - Pharma other
Acelyrin is a late-stage biopharmaceutical company developing drugs for the treatment of immunological diseases. Its core asset is targeted at a large and competitive market. The company's future depends on the success of its clinical program. This chart for the pharmaceutical sector shows the general expectations for innovation in immunology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772608042171 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Acelyrin, Inc. is a biopharmaceutical company specializing in immunology. Its value is determined by the potential of its pipeline of drugs. The overall economic sentiment reflected in this forecast influences the valuation of the entire biotech industry and the willingness of investors to fund clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772608042237 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Acelyrin Inc.
Acelyrin is a biopharmaceutical company focused on developing drugs to treat immunological diseases. For a late-stage clinical company, this chart is key. It shows how investors assess the potential future sales of its lead candidate, betting on its success in a large and competitive field.
P/S market segment - Pharma other
Acelyrin, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of immunological diseases. The company's valuation is based on the future potential of its key drug candidate. This chart, which displays average biotech valuations, helps understand how the market perceives Acelyrin's chances of success in its competitive field.
P/S of the market as a whole
Acelyrin is a biopharmaceutical company focused on acquiring and developing immunology drugs. This chart, which reflects market revenue estimates, serves as a proxy for Acelyrin's expectations. It demonstrates the value investors place on the potential of its leading candidates to become new standards of treatment for patients with inflammatory diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Acelyrin Inc.
Acelyrin is a clinical-stage biotech company focused on developing drugs for the treatment of immunological diseases. Its lead candidate targets a large and competitive market. This graph reflects investor expectations regarding the success of its clinical programs and its ability to compete with existing blockbusters.
%20P%2FS%20Acelyrin%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Acelyrin-Inc.&v=1772608042323 "The graph of the company's future (projected) P/S Acelyrin Inc.")
Future (projected) P/S of the market segment - Pharma other
Acelyrin, Inc. is a late-stage clinical development biopharmaceutical company focused on acquiring and developing drugs for the treatment of immunological diseases. This chart reflects average revenue expectations in the biotech sector. It provides an insight into the market perception of the potential of Acelyrin's lead candidate.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772608042408 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Acelyrin, Inc. is a biopharmaceutical company focused on developing and commercializing drugs to treat immunological diseases. This chart shows investor expectations for revenue growth. The company's success in bringing new, effective treatments to market for conditions such as psoriatic arthritis could unlock a huge market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772608042429 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Acelyrin Inc.
This chart illustrates the revenue of Acelyrin, Inc., a late-stage biopharmaceutical company focused on immunology. Its revenue at this stage is generated not from sales but from partnership fees, reflecting the progress of its key candidates in clinical trials.
Sales of companies in the market segment - Pharma other
Acelyrin, Inc. is a biopharmaceutical company focused on acquiring and developing promising immunology drugs. This chart illustrates the growth of the immunology drug market. Acelyrin's strategy of identifying innovative molecules at late stages of development allows it to accelerate their time to market, influencing the competitive landscape in this sector.
Overall market sales
Acelyrin, Inc. is a biopharmaceutical company developing treatments for immunological diseases. Its prospects depend on the success of clinical trials. The overall economic situation, shown in this chart, affects the availability of capital for funding long-term biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Acelyrin Inc.
Acelyrin is a biopharmaceutical company focused on developing treatments for immunological diseases. Future revenue depends on the success of its flagship drug in clinical trials and its market potential. The chart reflects analysts' confidence in this product.
%20sales%20of%20the%20company%20Acelyrin%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Acelyrin-Inc.&v=1772608042547 "Schedule of future (projected) sales of the company Acelyrin Inc.")
Future (projected) sales of companies in the market segment - Pharma other
Acelyrin is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of immunological diseases. Its strategy is to acquire promising assets and bring them to market quickly. This chart shows the forecast for the entire pharmaceutical market, where immunology remains one of the largest and most competitive areas.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772608042558 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Acelyrin is a late-stage biopharmaceutical company specializing in the development of drugs for the treatment of immunological diseases. Its valuation is dependent on the success of its lead drug candidate. This chart, reflecting market sentiment, influences investor valuation of the company ahead of key clinical and regulatory data releases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772608042607 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Acelyrin Inc.
Acelyrin is a biotech company developing drugs to treat immunological diseases. Being in late-stage clinical trials, it incurs significant expenses preparing for commercialization. This chart shows its net losses—investments in a potential blockbuster that could change the standard of care in immunology.
Market segment marginality - Pharma other
Acelyrin is a late-stage clinical development biopharmaceutical company specializing in immunological diseases. Profitability depends on the success of their lead drug candidate. This chart reflects the high research costs typical for a company preparing to potentially launch a new drug.
Market marginality as a whole
Acelyrin is a biopharmaceutical company focused on developing immunology drugs. Their lead candidate is designed to treat various inflammatory diseases. This overall profitability curve is irrelevant to them. Their value and future depend solely on the results of clinical trials and the market potential of their drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Acelyrin Inc.
Acelyrin is a rapidly growing biotech company. Its staff is growing significantly as it advances its promising drugs through late-stage clinical trials. This chart clearly demonstrates its ambition and the massive investment it is making in its R&D pipeline.
Share of the company's employees Acelyrin Inc. within the market segment - Pharma other
Acelyrin is a biopharmaceutical company focused on developing drugs to treat immunological diseases. This chart reflects its ambitious plans. It shows the size of the large and growing team required to conduct expensive and large-scale Phase III clinical trials for its lead drug candidate.
Number of employees in the market segment - Pharma other
Acelyrin, Inc. is a late-stage clinical development biopharmaceutical company focused on treating immunological diseases. This chart shows employment trends in the immunology sector. The growth in the number of clinicians and regulatory affairs specialists is driven by the company's advancement of its key drug through late-stage trials before market launch.
Number of employees in the market as a whole
Acelyrin is a biotech company focused on developing immunology drugs. Its success depends on the results of clinical trials and commercialization. A stable economic environment, reflected in this chart, is important for raising capital and for the future solvency of the healthcare system that will purchase its drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Acelyrin Inc. (SLRN)
Acelyrin, Inc. is a clinical-stage biotech company specializing in immunology. They develop drugs for the treatment of inflammatory diseases. This is a pure R&D business. The chart shows that the company's market value is a valuation of its scientific assets. The high market capitalization per employee reflects investors' faith in the potential of their leading drug candidates.
%20of%20the%20company%20Acelyrin%20Inc.%20(SLRN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Acelyrin-Inc.-SLRN&v=1772608043024 "Chart of market capitalization per employee (in thousands of dollars) of the company Acelyrin Inc. (SLRN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Acelyrin is a biopharmaceutical company focused on developing drugs for the treatment of immunological diseases. Like many companies in this sector, its value is determined by the potential of its clinical programs. This chart demonstrates the high market valuation of its research assets and prospects based on its small team of scientists.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772608043046 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Acelyrin is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of immunological diseases. The chart illustrates its estimated scientific potential. The very high market capitalization per employee reflects investors' high expectations for their lead drug, which has the potential to become a blockbuster.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772608043089 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Acelyrin Inc. (SLRN)
Acelyrin is a clinical-stage biotech company specializing in developing new treatments for immunological diseases. This is R&D. This chart shows the company's capital burn rate: the amount of capital the company spends on each scientist during expensive clinical trials.
%20Chart%20Acelyrin%20Inc.%20(SLRN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Acelyrin-Inc.-SLRN&v=1772608043134 "Company Profit Per Employee (in thousands of dollars) Chart Acelyrin Inc. (SLRN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Acelyrin is a biotech company specializing in immunology. Their key asset is a drug targeting a wide range of inflammatory diseases. Being in clinical development, the company is not profitable. This figure reflects the cost of conducting large-scale research.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772608043233 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Acelyrin (SLRN) is a clinical-stage biotech company specializing in immunology. It's an R&D company and has no profit. This chart shows its capital burn rate: the operating loss per team of scientists developing a new drug through expensive clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772608043287 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Acelyrin Inc. (SLRN)
Acelyrin is a biopharmaceutical company focused on developing treatments for immunological diseases. This chart reflects the progress of its research and development commercialization. Revenue growth at this stage will depend on the success of clinical trials and potential partnerships with major pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Acelyrin-Inc.-SLRN&v=1772608043328 "Sales chart per company employee Acelyrin Inc. (SLRN)")
Sales per employee in the market segment - Pharma other
Acelyrin (SLRN) is a biotech company focused on developing treatments for immunological diseases. While in the clinical stage, their revenue (if any) comes from partnerships. This chart shows how productive their R&D team is in monetizing their developments per scientist.
Sales per employee for the market as a whole
Acelyrin (SLRN) is a late-stage biotech developing drugs for the treatment of immunological diseases. The company is preparing to commercialize its lead candidate. This chart illustrates its pre-launch readiness: a large team of specialists is dedicated to R&D and launch preparation, which is an investment in future revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Acelyrin Inc. (SLRN)
Acelyrin is a biotech company that attracted much attention for its drug izokibep, but then suffered a major failure in clinical trials. The bearish sentiment shown in this chart reflects investor bets that its leading asset is "dead," and the rest of its pipeline is worthless.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Acelyrin-Inc.-SLRN&v=1772608043617 "Short Shares Chart for the Company Acelyrin Inc. (SLRN)")
Shares shorted by market segment - Pharma other
This chart shows the general investor skepticism toward the biotech sector, especially clinical-stage companies. Acelyrin specializes in immunology. The high short interest in the sector suggests that investors lack confidence in R&D success, fear fierce competition, or believe the sector's valuations are overvalued.
Shares shorted by the overall market
Acelyrin is a biotech company working in immunology. It's a classic R&D story. This chart measures the overall level of fear in the market. When it's high, investors are unwilling to fund multi-year clinical trials. They see "another unprofitable company" and sell it, fearing the "cash" will run out before success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Acelyrin Inc. (SLRN)
Acelyrin (SLRN) is a biotech company working in the field of immunology. The company's shares are binary and dependent on trial data. This oscillator tracks investor sentiment before the data release: it indicates peak optimism (above 70) or deep despair (below 30) after the results are released.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Acelyrin-Inc.-SLRN&v=1772608043740 "RSI 14 indicator chart for the company's stock Acelyrin Inc. (SLRN)")
RSI 14 Market Segment - Pharma other
Acelyrin is a clinical-stage biopharmaceutical company focused on immunology. Their flagship drug (izokibep) is being developed for the treatment of psoriatic arthritis and other inflammatory diseases. This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry as a whole.
RSI 14 for the overall market
Acelyrin (SLRN) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SLRN (Acelyrin Inc.)
Acelyrin is a biotech company developing drugs to treat immunological diseases. Their key asset is izokibep, which had high hopes. This chart shows the average 12-month analyst forecast. Their target price reflects high volatility and skepticism following mixed clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SLRN-Acelyrin-Inc.&v=1772608043834 "A chart showing analyst consensus forecasts for the expected stock price. SLRN (Acelyrin Inc.)")
The difference between the consensus estimate and the actual stock price SLRN (Acelyrin Inc.)
Acelyrin (SLRN) is a biotech company that made one of the biggest bets in history by licensing the drug Izlogibep for the treatment of autoimmune diseases. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their belief (or skepticism) in this potential blockbuster.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SLRN-Acelyrin-Inc.&v=1772608043901 "A chart showing the difference between the consensus forecast and the actual stock price. SLRN (Acelyrin Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Acelyrin (SLRN) is a biotech company focused on immunology. Its flagship drug is a treatment for hidradenitis suppurativa (sweat gland disease). This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe new dermatological drugs will be commercially successful.
Analysts' consensus forecast for the overall market share price
Acelyrin (SLRN) is a clinical-stage biopharmaceutical company focused on treating severe immunological diseases. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It is a clear indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Acelyrin Inc.
Acelyrin is a clinical-stage biotech company focused on developing immunology drugs. Like many biotechs, their value is determined by the potential of one or two leading candidates. This chart is a composite index reflecting the market's assessment of scientific prospects, clinical trial risks, and the adequacy of funding to complete development.
AKIMA Market Segment Index - Pharma other
Acelyrin (SLRN) is another promising pharma. It's a biotech betting on a potential blockbuster (Izokibep) for inflammatory diseases. This chart compares their composite index to the sector average, showing their position in the R&D race.
The AKIM Index for the overall market
Acelyrin is a biopharmaceutical company developing and commercializing immunological drugs (izokibep). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which has faced clinical setbacks since its major IPO, compares to overall trends.
